Alexander Ruthven, MD
Family Medicine · Port Huron, MINPI 1194757864
Payments from drug & device makers
Across 163 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$289
- AstraZeneca$248
- Pfizer$247
- AbbVie$220
- Amarin Pharma, Inc.$176
- Merck$167
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,56099%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 17 | $289 |
| AstraZeneca | 14 | $248 |
| Pfizer | 22 | $247 |
| AbbVie(2 entities) | 12 | $220 |
| Amarin Pharma, Inc. | 11 | $176 |
| Merck | 11 | $167 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $157 |
| Boehringer Ingelheim | 8 | $125 |
| Johnson & Johnson | 7 | $119 |
| Novo Nordisk | 8 | $103 |
| Amgen | 6 | $86 |
| Mylan Specialty L.p. | 5 | $80 |
| SK Life Science, Inc. | 4 | $67 |
| Abbott | 3 | $56 |
| Actelion Pharmaceuticals US, Inc. | 2 | $47 |
| Dexcom, Inc. | 2 | $39 |
| Bayer | 2 | $39 |
| Orexo US, Inc. | 2 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Advanced Respiratory, Inc | 2 | $31 |
| Almatica Pharma LLC | 2 | $29 |
| Nevro Corp. | 1 | $26 |
| Biogen | 1 | $22 |
| Alkermes, Inc. | 1 | $21 |
| Indivior Inc. | 1 | $20 |
| Gilead | 1 | $19 |
| GSK | 1 | $17 |
| Lilly USA, LLC | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
| Phathom Pharmaceuticals, Inc. | 1 | $6 |
How this compares
$2,590 in reported general payments places this provider in the 80th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 183 | $215,049 |
| EliquisApixaban | 175 | $156,140 |
| FarxigaDapagliflozin Propanediol | 145 | $139,568 |
| JardianceEmpagliflozin | 95 | $96,254 |
| MounjaroTirzepatide | 72 | $89,606 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 111 | $71,447 |
| OzempicSemaglutide | 46 | $66,914 |
| XareltoRivaroxaban | 63 | $64,555 |
| RybelsusSemaglutide | 34 | $54,320 |
| EntrestoSacubitril/Valsartan | 44 | $46,254 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 165 | $35,350 |
| SymbicortBudesonide/Formoterol Fumarate | 108 | $32,268 |
| CaplytaLumateperone Tosylate | 13 | $19,855 |
| VraylarCariprazine Hcl | 12 | $16,850 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 84 | $14,866 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $13 | $304,655255 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $248 | $176,999266 claims |
| PfizerEliquis | $247 | $156,140175 claims |
| Novo NordiskOzempic, Rybelsus, Novolog Mix 70-30 | $103 | $128,87991 claims |
| Boehringer IngelheimJardiance | $125 | $96,25495 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $17 | $82,899133 claims |
| Johnson & JohnsonXarelto | $119 | $64,55563 claims |
| NovartisEntresto | $289 | $46,25444 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $157 | $19,85513 claims |
| AbbVieVraylar | $220 | $16,85012 claims |
| Indivior Inc.Suboxone | $20 | $6,14611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Port Huron
- Pietro CavataioPort Huron$40K
- Michele RaymondPort Huron$24K
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.